Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer.

Scientific Reports
Paavo V H RaittinenTeemu J Murtola

Abstract

Prostate cancer patients using cholesterol-lowering statins have 30% lower risk of prostate cancer death compared to non-users. The effect is attributed to the inhibition of the mevalonate pathway in prostate cancer cells. Moreover, statin use causes lipoprotein metabolism changes in the serum. Statin effect on serum or intraprostatic lipidome profiles in prostate cancer patients has not been explored. We studied changes in the serum metabolomic and prostatic tissue lipidome after high-dose 80 mg atorvastatin intervention to expose biological mechanisms causing the observed survival benefit. Our randomized, double-blind, placebo-controlled clinical trial consisted of 103 Finnish men with prostate cancer. We observed clear difference in post-intervention serum lipoprotein lipid profiles between the study arms (median classification error 11.7%). The atorvastatin effect on intraprostatic lipid profile was not as clear (median classification error 44.7%), although slightly differing lipid profiles by treatment arm was observed, which became more pronounced in men who used atorvastatin above the median of 27 days (statin group median classification error 27.2%). Atorvastatin lowers lipids important for adaptation for hypoxic microe...Continue Reading

References

Jan 10, 2001·International Journal of Cancer. Journal International Du Cancer·Y Chen, M Hughes-Fulford
Oct 9, 2003·Clinical Pharmacokinetics·Hans Lennernäs
Apr 6, 2012·World Journal of Urology·Otis W Brawley
Jul 25, 2012·Current Opinion in Pharmacology·Kristine PeltonKeith R Solomon
May 15, 2013·Proceedings of the National Academy of Sciences of the United States of America·Jurre J KamphorstJoshua D Rabinowitz
Jul 23, 2013·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Wambui G Gathirua-Mwangi, Jianjun Zhang
Jul 6, 2014·Trends in Cell Biology·Daniel Ackerman, M Celeste Simon
Feb 19, 2015·Circulation. Cardiovascular Genetics·Pasi SoininenMika Ala-Korpela
Jul 8, 2016·International Journal of Molecular Sciences·Gagan Deep, Isabel R Schlaepfer
Nov 3, 2016·Nature Reviews. Urology·Mahmoud A AlfaqihStephen J Freedland
Dec 29, 2017·Prostate Cancer and Prostatic Diseases·Juzar JamnagerwallaStephen J Freedland
Jul 13, 2018·Cancer Communications·Ching-Ying Kuo, David K Ann
Sep 9, 2018·Lipids in Health and Disease·Joshua S BrzozowskiJudith Weidenhofer
Feb 8, 2019·Science Translational Medicine·Matthew J WattRenea A Taylor
Jun 25, 2019·The Prostate·Emma KnuuttilaTeemu J Murtola

❮ Previous
Next ❯

Methods Mentioned

BETA
nuclear magnetic resonance
NMR

Clinical Trials Mentioned

NCT01821404

Software Mentioned

R
randomForest

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.